PUT1 Antibody

Basic Research Questions

• What is PUT1 and what related antibodies are available for research?

PUT1 (putative DNA/chromatin binding motif) is an alias for KDM5B (Lysine-specific demethylase 5B), also known as JARID1B, PLU-1, RBBP2H1A, and several other names . KDM5B is a large (1,544 amino acid) nuclear protein that interacts with brain factor-1 (BF-1) and paired box 9 (PAX9), both developmental transcription factors . It belongs to the testis-cancer antigen group of proteins and is a member of the ARID family of DNA binding proteins with strong transcriptional repression properties .

Both monoclonal and polyclonal antibodies against this target are commercially available:

• Polyclonal rabbit anti-KDM5B antibodies

• Monoclonal mouse anti-JARID1B antibodies

• Recombinant rabbit monoclonal antibodies

• What applications are PUT1/KDM5B antibodies validated for?

Based on scientific literature and technical documentation, PUT1/KDM5B antibodies have been validated for multiple research applications:

Most published research utilizes these antibodies for detecting KDM5B expression in cancer cell lines, particularly breast cancer, where the protein shows upregulation .

• What is the structure and function of the PUT1/KDM5B protein that these antibodies target?

PUT1/KDM5B is a multi-domain protein containing:

• An N-terminal acidic/polyGln transactivation region (amino acids 34-99)

• A non-destabilizing PEST sequence (amino acids 117-165)

• A C-terminal Ets DNA-binding domain (amino acids 170-253)

Functionally, KDM5B acts as a histone demethylase that regulates gene expression through epigenetic mechanisms. It shows restricted expression in adult tissues, with high expression in testis and transient expression in pregnant mammary glands . Both the gene and protein are significantly upregulated in breast cancer, suggesting its potential role as a biomarker .

• How should I validate a new PUT1/KDM5B antibody before use in my experiments?

Proper antibody validation is critical for generating reproducible research results . For PUT1/KDM5B antibodies, implement the following validation protocol:

• Perform Western blot analysis using positive control cell lines such as K562 (human chronic myelogenous leukemia), Daudi (human Burkitt's lymphoma), or THP-1 (human acute monocytic leukemia)

• Include appropriate negative controls (isotype controls and/or cells with known low/no expression)

• Verify protein size (~40-45 kDa, though the predicted molecular weight is 31 kDa)

• For functional studies, compare results across multiple antibody clones if available

• Consider additional validation through knockout/knockdown experiments

• Document all validation experiments thoroughly for publication requirements

Advanced Research Questions

• How do I optimize PUT1/KDM5B antibodies for immunohistochemistry applications?

Optimization of PUT1/KDM5B antibodies for IHC requires methodical adjustment of multiple parameters to achieve the optimal signal-to-noise ratio :

• Antigen retrieval optimization:

  • Test both heat-induced epitope retrieval (HIER) methods with citrate buffer (pH 6.0) and EDTA buffer (pH 9.0)

  • Optimize retrieval duration (typically 10-30 minutes)

• Antibody concentration titration:

  • For polyclonal antibodies, begin with dilutions between 1:50-1:200

  • Prepare a dilution series (e.g., 1:25, 1:50, 1:100, 1:200) to identify optimal concentration

• Incubation conditions:

  • Test both overnight incubation at 4°C and 1-2 hour incubation at room temperature

  • Optimize detection system incubation times

• Detection system selection:

  • Compare polymer-based vs. avidin-biotin complex (ABC) detection systems

  • Consider amplification systems for low-abundance targets

Document all optimization steps in a standardized protocol, as different tissue types and fixation methods may require adjustments to these parameters .

• What controls should I include when using PUT1/KDM5B antibodies in flow cytometry?

For rigorous flow cytometry experiments with PUT1/KDM5B antibodies, implement the following controls:

• Isotype control: Match the host species, isotype, and concentration of your primary antibody (e.g., for mouse monoclonal antibodies, use mouse IgG at the same concentration)

• Fluorophore-matched controls: Include single-color controls for each fluorophore in your panel

• Compensation controls: When using multiple fluorophores, prepare single-color compensation controls

• Biological controls:

  • Positive control: THP-1 cells (human acute monocytic leukemia) show good KDM5B expression

  • Negative control: Use cell lines with low/no KDM5B expression or KDM5B-knockdown cells

• Fixation/permeabilization controls: Since KDM5B is a nuclear protein, compare different permeabilization protocols (e.g., paraformaldehyde fixation with saponin permeabilization has shown good results)

• How do epitope differences affect PUT1/KDM5B antibody selection for specific applications?

Understanding epitope recognition is crucial for selecting appropriate PUT1/KDM5B antibodies:

• Epitope mapping considerations:

  • N-terminal targeted antibodies (amino acids 1-169): Useful for detecting both full-length and potential truncated variants; human and mouse PUT1/KDM5B share 88% amino acid identity in this region

  • C-terminal targeted antibodies: May miss truncated variants but can be more specific for full-length protein

  • Specific domain targeting: Antibodies recognizing functional domains (e.g., the DNA-binding domain) may be useful for mechanistic studies

• Glycosylation effects:

  • KDM5B has N-glycosylation sites at positions 49, 74, 116, and 58

  • Antibodies recognizing regions containing N58 in the BC loop may show altered binding if glycosylation status changes

  • For applications sensitive to post-translational modifications, select antibodies with epitopes away from known glycosylation sites

• Application-specific considerations:

  • For Western blot: Denatured epitopes are accessible, so most antibodies work well

  • For IP/ChIP: Antibodies must recognize native conformations

  • For IHC: Fixation-resistant epitopes are preferable

• What approaches can resolve contradictory results when using different PUT1/KDM5B antibodies?

When faced with inconsistent results using different PUT1/KDM5B antibodies, implement this systematic troubleshooting approach:

• Epitope comparison:

  • Map the epitopes recognized by each antibody

  • Different antibodies may recognize different isoforms or post-translationally modified variants

• Validation status assessment:

  • Review validation data for each antibody

  • Consider performing knockout/knockdown validation experiments

• Application-specific optimization:

  • Different antibodies may require different optimization for each application

  • Test different fixation/permeabilization methods, especially for IHC/ICC

• Alternative detection methods:

  • Confirm results using orthogonal methods (e.g., mass spectrometry)

  • Use mRNA detection methods (RT-PCR, RNA-seq) to correlate with protein data

• Lot-to-lot variation analysis:

  • Document lot numbers and test multiple lots if possible

  • Request technical support from manufacturers for known lot-specific issues

• How can I modify PUT1/KDM5B antibodies for specialized research applications?

For specialized applications requiring modified PUT1/KDM5B antibodies:

• Fragment generation:

  • Fab fragments: Digest antibodies with papain to generate antigen-binding fragments without Fc-mediated functions

  • F(ab')₂ fragments: Use pepsin digestion to create bivalent antigen-binding fragments without Fc regions

  • Single-chain Fv (scFv): Engineer variable domains connected by a synthetic peptide linker for improved tissue penetration

• Conjugation strategies:

  • Direct labeling: Conjugate fluorophores, enzymes, or biotin to purified antibodies using commercial conjugation kits

  • Site-specific conjugation: Use engineered antibodies with unique reactive sites to control conjugation position

  • Ratios: Optimize labeling ratios to maintain binding while maximizing signal

• Advanced modifications:

  • Bispecific antibodies: Create hybrid antibodies targeting both PUT1/KDM5B and another protein of interest

  • Recombinant engineering: Use protein diffusion AI approaches to design optimized binding domains

• What are the latest developments in PUT1/KDM5B antibody engineering and applications?

Recent advances in PUT1/KDM5B antibody research include:

• AI-assisted antibody design:

  • Computational approaches using protein diffusion models have enabled the design of novel antibodies with optimized binding properties

  • These technologies allow for rational design of binding domains that target specific epitopes while optimizing biophysical properties

• Therapeutic potential:

  • Given KDM5B's upregulation in breast cancer, antibodies against this target are being explored for potential diagnostic and therapeutic applications

  • Similar to PD-1 antibody development, structure-guided engineering approaches may lead to improved targeting of epigenetic modulators like KDM5B

• Multiplexed detection:

  • Advanced techniques combining multiple antibodies for simultaneous detection of KDM5B and other epigenetic regulators

  • Integration with mass cytometry and imaging mass cytometry for high-dimensional analysis

• Enhanced validation frameworks:

  • Implementation of comprehensive validation standards following recent initiatives to address the "antibody characterization crisis"

  • Development of recombinant antibodies with consistent performance characteristics across different lots

Additional Resources and Technical Tips

• How should PUT1/KDM5B antibodies be stored and handled for optimal performance?

To maintain PUT1/KDM5B antibody performance:

• Storage conditions:

  • Store unused antibody at -20°C to -70°C for long-term stability (up to 12 months)

  • For reconstituted antibodies, store at 2-8°C for up to 1 month under sterile conditions

  • For longer storage after reconstitution, aliquot and store at -20°C to -70°C (stable for up to 6 months)

• Handling practices:

  • Avoid repeated freeze-thaw cycles by preparing small, single-use aliquots

  • Before opening, briefly centrifuge vials (20-30 seconds) to collect contents at the bottom of the tube

  • Use sterile technique when handling antibody solutions

• Reconstitution guidelines:

  • Follow manufacturer's recommendations for reconstitution buffer composition

  • For lyophilized antibodies, reconstitute using sterile buffers at recommended concentrations

  • Document reconstitution date and conditions

• What troubleshooting approaches help resolve common issues with PUT1/KDM5B antibodies?

When encountering problems with PUT1/KDM5B antibody experiments:

• Weak or no signal:

  • Verify antibody activity with positive control samples

  • Increase antibody concentration or incubation time

  • Optimize antigen retrieval (for IHC/ICC) or protein extraction methods

  • Check detection system components

• High background:

  • Increase blocking time or blocker concentration

  • Decrease primary antibody concentration

  • Increase wash steps duration and number

  • Test alternative blocking agents

• Non-specific bands in Western blot:

  • Increase blocking stringency

  • Optimize SDS-PAGE conditions to improve resolution

  • Consider preabsorption of antibody with non-specific proteins

  • Note that KDM5B runs at approximately 40-45 kDa despite its predicted 31 kDa size

• Lot-to-lot variation:

  • Document lot numbers and maintain reference samples

  • Consider switching to recombinant monoclonal antibodies for greater consistency

  • Perform side-by-side testing when transitioning to new antibody lots